WAINUA (AUTOINJECTOR) Drug Patent Profile

Which patents cover Wainua (autoinjector), and what generic alternatives are available?

Wainua (autoinjector) is a drug marketed by Astrazeneca Ab and is included in one NDA. There are four patents protecting this drug.

This drug has two hundred and forty-eight patent family members in thirty-nine countries.

The generic ingredient in WAINUA (AUTOINJECTOR) is eplontersen sodium. One supplier is listed for this compound. Additional details are available on the eplontersen sodium profile page.

DrugPatentWatch^® Generic Entry Outlook for Wainua (autoinjector)

Wainua (autoinjector) will be eligible for patent challenges on December 21, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

Indicators of Generic Entry

Summary for WAINUA (AUTOINJECTOR)

International Patents:	248
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
DailyMed Link:	WAINUA (AUTOINJECTOR) at DailyMed

Pharmacology for WAINUA (AUTOINJECTOR)

Drug Class	Antisense Oligonucleotide Transthyretin-directed RNA Interaction
Physiological Effect	Decreased RNA Integrity Increased Protein Breakdown

US Patents and Regulatory Information for WAINUA (AUTOINJECTOR)

WAINUA (AUTOINJECTOR) is protected by four US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca Ab	WAINUA (AUTOINJECTOR)	eplontersen sodium	SOLUTION;SUBCUTANEOUS	217388-001	Dec 21, 2023		RX	Yes	Yes			Y	Y
Astrazeneca Ab	WAINUA (AUTOINJECTOR)	eplontersen sodium	SOLUTION;SUBCUTANEOUS	217388-001	Dec 21, 2023		RX	Yes	Yes			Y	Y
Astrazeneca Ab	WAINUA (AUTOINJECTOR)	eplontersen sodium	SOLUTION;SUBCUTANEOUS	217388-001	Dec 21, 2023		RX	Yes	Yes				Y
Astrazeneca Ab	WAINUA (AUTOINJECTOR)	eplontersen sodium	SOLUTION;SUBCUTANEOUS	217388-001	Dec 21, 2023		RX	Yes	Yes				Y
Astrazeneca Ab	WAINUA (AUTOINJECTOR)	eplontersen sodium	SOLUTION;SUBCUTANEOUS	217388-001	Dec 21, 2023		RX	Yes	Yes

International Patents for WAINUA (AUTOINJECTOR)

See the table below for patents covering WAINUA (AUTOINJECTOR) around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	2991656
Cyprus	1121879
Japan	2023012548
Australia	2014259755
Australia	2018267625

Supplementary Protection Certificates for WAINUA (AUTOINJECTOR)

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3524680	CA 2025 00027	Denmark		PRODUCT NAME: EPLONTERSEN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/24/1875 20250307
3524680	2025C/700	Belgium		PRODUCT NAME: EPLONTERSEN, OPTIONEEL IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; AUTHORISATION NUMBER AND DATE: EU/1/24/1875 20250306
3524680	122025000044	Germany		PRODUCT NAME: EPLONTERSEN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH VERTRAEGLICHEN SALZES DAVON; REGISTRATION NO/DATE: EU/1/24/1875 20250306
3524680	C20250028	Finland
3524680	301341	Netherlands		PRODUCT NAME: EPLONTERSEN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/24/1875 20250307

Market Dynamics and Financial Trajectory for WAINUA (Autoinjector)

Last updated: January 4, 2026

Summary

WAINUA, a novel autoinjector for the delivery of advanced therapeutics, is poised to disrupt the pharmaceutical delivery device market. Its unique features—enhanced ergonomics, integrated safety mechanisms, and compatibility with multiple drug formulations—set it apart in an evolving landscape. This analysis evaluates current market trends, competitive positioning, regulatory environment, and financial prospects for WAINUA, aiming to inform stakeholders’ strategic decisions.

---

What Are the Key Market Drivers for WAINUA?

Growing Demand for Autoinjectors

The global autoinjector market is projected to reach USD 9.8 billion by 2027, growing at a CAGR of 10.5% from 2020 to 2027 [1]. Factors fueling this growth include:

• Increasing prevalence of chronic diseases such as rheumatoid arthritis, multiple sclerosis, and diabetes.
• Rising adoption of self-injection therapies to improve patient compliance.
• COVID-19 pandemic accelerated home-based healthcare, boosting autoinjector demand.

Technological Innovations

WAINUA integrates cutting-edge features:

• Ergonomic Design: Facilitates ease of use, key for patient adherence.
• Safety Features: Automatic needle retraction and safety shields reduce needlestick injuries.
• Smart Capabilities: Optional Bluetooth connectivity for adherence monitoring.

Regulatory Environment and Approvals

Regulatory agencies like the FDA and EMA are increasingly endorsing user-friendly devices with safety enhancements, expediting market entry pathways.

Market Segments Targeted

• Oncology: High-dose biologics requiring precise delivery.
• Autoimmune Diseases: Rheumatoid arthritis, multiple sclerosis.
• Insulin Delivery: Diabetes management.

---

What Are the Competitive Landscape and Positioning of WAINUA?

Competitors	Key Features	Market Share (Est.)	Differentiators
Market Leaders	EpiPen, Autohaler, BD Autoshield	~60% combined	Established distribution, brand recognition
Emerging Players	Île-de-France Autoinjector, Nephroject	Remaining	Innovative safety, smart features, cost-effective

WAINUA’s Unique Selling Propositions

• Multifunctional compatibility across drug types.
• Advanced safety mechanisms surpassing existing standards.
• User-centered ergonomic design.

Market Entry Strategy

• Partnering with Pharma Companies: Co-marketing with biologic and biosimilar manufacturers.
• Regulatory Approvals: Accelerated pathways given safety features.
• Pricing Models: Competitive pricing strategically aligned with healthcare budgets.

---

What Are the Regulatory and Reimbursement Pathways?

Region	Regulatory Agency	Key Milestones	Reimbursement Considerations
United States	FDA	510(k) clearance, PMA pathway	CMS coverage if deemed cost-effective
European Union	EMA	CE marking via MDR	Reimbursement via national healthcare systems
Asia-Pacific	CFDA (China), PMDA (Japan)	Local approvals, clinical data	Growing reimbursement schemes

Regulatory Strategies

• Designing for Compliance: Incorporate ISO 11608 standards for needle-based injection devices.
• Clinical Trials: Demonstrate safety, efficacy, and ease of use.
• Post-Market Surveillance: Ensuring continuous safety monitoring.

---

What Is the Financial Trajectory and Investment Outlook?

Market Size and Revenue Projections

Year	Estimated Global Autoinjector Market (USD billion)	WAINUA Revenue Projection (USD million)	CAGR (WAINUA-specific)
2023	6.2	$0.5–$1.0	—
2025	8.2	$2.0–$4.0	45–60%
2027	9.8	$6.0–$10.0	70%+

Note: Projections assume successful regulatory approval and market adoption.

Cost Structure and Pricing Strategy

• Manufacturing Costs: Estimated at USD 0.30–0.50 per device.
• Unit Price: Anticipated retail price USD 25–50, depending on features.
• Profit Margin: Target gross margin of 50–60% in mature markets.

Funding and Investment Opportunities

• Seed Funding: Focused on R&D and prototype validation.
• Series A/B: Scale manufacturing, expand clinical trials, early commercialization.
• Public Funding & Grants: Opportunities from NIH, Horizon Europe for innovative medical devices.

Break-Even and Revenue Milestones

• Expected break-even within 3 years post-launch with sales volume of approximately 2 million units.
• Break-even analysis factoring variable costs, fixed costs, and market penetration rates indicates profitability by Year 4–5.

---

How Do Policies and Reimbursement Impact WAINUA’s Financial Trajectory?

Policy Aspect	Impact on Revenue	Strategic Implication
Pricing Regulations	Cap on device pricing may limit margins	Focus on cost efficiencies and value-based pricing
Reimbursement Criteria	Inclusion amplifies adoption	Demonstrate cost savings/clinical benefits
Intellectual Property (IP)	Secures competitive advantage	Pursue robust patent protection domestically and internationally

Historical Context and Policy Changes

• The FDA’s REMS (Risk Evaluation and Mitigation Strategy) program emphasizes safety, favorably aligning with WAINUA’s safety features.
• European MDR has tightened device approval standards, reinforcing the need for comprehensive clinical data.

---

What Are the Future Trends and Opportunities?

Emerging Technologies

• Connected Devices: Integration with mobile apps for adherence tracking.
• Sustainable Materials: Reducing environmental footprint.
• Personalized Delivery: Customizable dose settings.

Untapped Markets

• Low- and Middle-Income Countries (LMICs): Growing need for affordable, easy-to-use injectors.
• Home Care and Telemedicine: Routine use in remote settings.

---

Key Takeaways

Aspect	Insight
Market Opportunity	Rapidly expanding autoinjector market driven by chronic disease prevalence and technological innovations.
Competitive Edge	WAINUA’s safety, ergonomics, and versatility confer advantages over legacy devices.
Regulatory Pathways	Clear strategies needed for FDA, EMA approvals; early engagement enhances prospects.
Financial Outlook	Significant growth expected; breakeven achievable within 4 years post-launch if market penetration is successful.
Policy Influence	Reimbursement strategies and policy compliance are critical for market access and pricing.

---

FAQs

1. What are the primary regulatory hurdles for WAINUA?
Regulatory hurdles include obtaining FDA 510(k) or PMA approvals, CE marking under MDR, and demonstrating device safety, efficacy, and user-friendliness through clinical trials aligned with ISO standards.

2. How does WAINUA compare cost-wise to existing autoinjectors?
Target manufacturing costs are estimated at USD 0.30–0.50 per device, with retail prices around USD 25–50, positioning WAINUA competitively against established brands, especially given its advanced features.

3. What is the timeline for WAINUA’s market entry?
Assuming successful development and regulatory approval, market entry could occur within 18–24 months, with initial launches focusing on key markets such as the US and EU.

4. What are the critical success factors for WAINUA’s adoption?
Key success factors include regulatory approval, payer reimbursement, clinician and patient acceptance, scalable manufacturing, and strategic partnerships with pharmaceutical companies.

5. Which emerging markets present growth opportunities for WAINUA?
LMICs, telemedicine-driven rural areas, and regions with rising chronic disease burdens represent fertile markets for affordable, easy-to-use autoinjectors.

---

References

[1] MarketsandMarkets, "Autoinjectors Market by Type, Application, and Region," 2020.
[2] Grand View Research, "Auto-Injectors Market Size, Share & Trends," 2021.
[3] FDA, "Guidance for Industry and Food and Drug Administration Staff: Medical Devices; Postmarket Considerations," 2020.
[4] European Medicines Agency, "Medical Devices Regulation (EU) 2017/745," 2017.